Main Uses and Benefits of Alerfree C

Alerfree C is a combination medication formulated to address symptoms associated with upper respiratory conditions that involve both allergic reactions and nasal congestion. It integrates an antihistamine with a decongestant to provide multi-symptom relief.

Relief of Allergic Symptoms

The antihistamine component of Alerfree C is used to manage common symptoms of allergic rhinitis (hay fever) and other upper respiratory allergies. These include:

• Sneezing: Reducing the frequency and severity of sneezing fits.
• Itching: Alleviating itching of the nose, throat, and roof of the mouth.
• Watery Eyes: Managing itchy, red, or tearing eyes caused by environmental allergens.
• Runny Nose: Decreasing excessive nasal discharge.

Management of Nasal Congestion

The decongestant element focuses on the physical blockage of the nasal passages. It works by reducing the swelling of the mucous membranes in the nose, which helps to:

• Improve Airflow: Clear the nasal passages to facilitate easier breathing through the nose.
• Reduce Pressure: Ease the feeling of fullness or pressure often felt in the sinuses and ears during an allergic episode or a cold.

Combined Therapeutic Action

By addressing both the histamine response and the inflammatory swelling of nasal tissues, Alerfree C provides comprehensive management for individuals experiencing complex respiratory symptoms. This dual action is particularly beneficial when allergies are accompanied by significant sinus congestion, as standard antihistamines alone may not effectively resolve a blocked nose.

Regulatory References

1. NIH DailyMed Overview

The official regulatory profile for Alerfree C (Levocetirizine dihydrochloride) defines eligibility based on age, organ function, and pre-existing conditions.

Populations for whom use is Contraindicated

The medicine must not be used by patients with a known hypersensitivity to levocetirizine, its parent compound cetirizine, or other piperazine derivatives. Use is also strictly prohibited for patients with End-Stage Renal Disease (Creatinine Clearance less than 10 mL/min) and for children 6 months to 11 years old with any degree of impaired renal function.

Age-Related Eligibility and Restrictions

Alerfree C is approved for adults and adolescents (12 years and older), and for children as young as 6 months of age, typically using the oral solution. The film-coated tablet formulation is not recommended for children under 6 years due to the inability to achieve appropriate dose adaptation. Safety has not been established for infants under 6 months.

Condition-Specific Rules and Caution

Eligibility for patients 12 years and older with mild to severe renal impairment is conditional and requires a formal adjustment. No adjustment is required for solely hepatic impairment. Caution is formally advised for patients with predisposing factors for urinary retention (e.g., prostatic hyperplasia) and those with epilepsy or risk of convulsion. Use may be considered during pregnancy, if necessary, and is subject to caution during lactation.

Interactions with other medicines and products

Official regulatory documents structure the interaction profile for combination products by identifying two primary areas of constraint: additive pharmacodynamic effects and additive drug exposure.

Interaction Category	Substance Classes and Restrictions
Additive CNS Depressants	Other sedative drugs, tranquilizers, or any product that causes sleepiness. Co-administration is explicitly warned against without consultation due to the potential for intensified effects, which are a direct result of additive pharmacodynamic activity.
Additive Analgesic Exposure	Other medicinal products containing paracetamol or acetaminophen. A restriction is placed on co-administration because this product contains that substance, and combining it with other products containing the same ingredient can lead to exceeding the maximum recommended daily limit.
Non-Medicinal Interactions	Ethanol (Alcohol). The consumption of alcohol is advised to be avoided because it can potentiate the effects of the drug's components, specifically enhancing effects like drowsiness or sleepiness.
Sympathomimetic Interactions	Medicines that have a similar effect on the cardiovascular system (e.g., Monoamine Oxidase Inhibitors - MAOIs). Co-administration with MAOIs is prohibited due to the risk of severe blood pressure elevation, which is a key interaction-related constraint established in regulatory labeling.
Pharmacokinetic Effects	Theophylline. Official studies have documented that co-administration with theophylline may result in decreased clearance of the antihistamine component.

These interaction classifications mandate constraints for the user and prescriber, focusing on avoiding combinations that lead to dangerous additive central nervous system effects or risk exceeding safe concentration limits of individual components. The profile requires that the product not be used alongside certain classes of medicines to mitigate severe pharmacodynamic and exposure-related risks documented by government authorities.

Selective Histamine boldsymbolHmathbf1-Receptor Antagonism

The drug's primary action is the high-affinity antagonism and inverse agonism of the peripheral Histamine H1-receptor (H1R). By binding to the H1R, Levocetirizine blocks the binding site for histamine, thereby interrupting the molecular cascade that triggers increased vascular permeability and localized nerve stimulation. This action modifies the initial steps of the histamine-driven signaling pathway.

Regulation of Vascular Consequences and Cellular Migration

This mechanism of H1R blockade leads directly to the physiological consequence of limiting excessive fluid leakage from capillaries into surrounding tissues. This action modifies localized microvascular dynamics and limits plasma exudation, affecting local tissue volume. Furthermore, the drug exhibits a secondary action by inhibiting the recruitment and adhesion of eosinophils to vascular endothelium, thereby affecting the migration of cells involved in cellular responses.

Focused Peripheral Activity Profile

The drug's physicochemical properties restrict its ability to distribute across the Blood-Brain Barrier (BBB). Consequently, the antagonistic action is primarily localized to peripheral tissues, including the respiratory tract, skin, and vasculature. This differentiated profile results in a physiological effect concentrated on peripheral organ systems, without significant modulation of central H1-receptor activity.

Official Administration Guidelines

Alerfree C is intended for oral administration and is taken as a single daily dose. The dosing schedule is defined across age groups, with specific requirements for patients with reduced kidney function to ensure the medicine is used appropriately for various patient needs.

---

Standard Labeled Dosing

Population	Standard Dose (Once Daily)	Maximum Recommended Dose
Adults and Adolescents (ge 12 yrs)	5 mg (or 2.5 mg for adequate control)	5 mg per day
Children 6 to 11 yrs	2.5 mg	2.5 mg per day
Children 6 months to 5 yrs	1.25 mg (Oral Solution only)	1.25 mg per day

---

Procedural Instructions

The total daily dose should be taken as a single intake, and administration is recommended in the evening. Alerfree C may be consumed with or without food. The 5 mg tablet is scored, facilitating its division to administer the 2.5 mg dose where specified. The tablet must be swallowed whole with liquid.

Dose Adjustment and Duration of Use

Standard protocols require the dosing interval to be adjusted in patients 12 years and older with renal impairment (reduced kidney function). For instance, patients with severe impairment (creatinine clearance 10-30 mL/min) receive the medicine twice weekly, administered once every 3 to 4 days. No dosage adjustment is specified for patients with solely hepatic impairment.

For episodic conditions, treatment may be stopped when symptoms disappear and restarted upon recurrence. In persistent conditions, continuous therapy may be proposed throughout the period of allergen exposure.

Research Evidence / Overview of Studies for Alerfree C

Evidence from Studies for Seasonal Allergic Rhinitis (SAR)

Research examining the use of Alerfree C for seasonal allergies, such as hay fever, was conducted primarily through short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, typically lasting about two to four weeks. Researchers included both adults and adolescents (12 years and older) in these trials, often focusing on subjects who had existing sensitivity to specific seasonal allergens. The main study outcomes examined were related to physical discomfort and daily functioning, specifically monitoring the composite scores like the Total 5 Symptom Score (T5SS).

Evidence from Studies for Perennial Allergic Rhinitis (PAR)

Evidence for Alerfree C in Perennial Allergic Rhinitis (PAR) was also developed using randomized, controlled trials. These trials were applied in studies examining patient-reported experiences related to chronic, ongoing symptoms. Studies explored the use of Alerfree C in adults and children (6 years of age and older) and monitored the outcomes reflecting daily functioning over longer periods, with documentation of measurements recorded over time intervals lasting up to six months. Comparative evidence is lacking for comprehensive, head-to-head comparisons against all currently available second-generation antihistamines.

Evidence from Studies for Chronic Idiopathic Urticaria (CIU)

Alerfree C was studied for Chronic Idiopathic Urticaria (CIU), a condition involving periods of heightened symptoms such as persistent itching and hives. Research has focused on RCTs and subsequent systematic reviews. Studies monitored outcomes linked to inflammatory or irritative states and patient-reported outcomes, specifically examining the Urticaria Activity Score (UAS). Evidence quality varies across studies, and the certainty remains low for certain comparative outcomes due to modest sample sizes in the individual trials combined in the reviews.

---

Long-Term Studies and Follow-up Durations

Research exploring the long-term patterns of symptom control was observed in some studies, with follow-up durations extended up to six months in controlled research settings for perennial conditions. However, the long-term effects are not fully established beyond the observation periods of these intermediate trials. There is limited information for long-term outcomes addressing the durability of symptom control over many consecutive years of use.

Evidence in Special Populations and Gaps

Alerfree C was evaluated in use across a wide range of ages, including adults, adolescents, and children. Pharmacokinetic studies was observed in very young children, down to one year of age. The available research primarily reflects the populations studied, and information for certain groups remains limited, such as dedicated studies focusing specifically on older adults or patients with multiple clinically significant comorbid diseases. This highlights areas where further research is needed.

Key Studies & References

1. FDA Prescribing Information for Xyzal (Levocetirizine dihydrochloride) - Classification
2. Levocetirizine Dihydrochloride Oral Solution - Consumer Overview (DailyMed)
3. Levocetirizine - StatPearls (NIH/NCBI Bookshelf)

Common questions about Alerfree C (FAQ)

Q: How quickly does Alerfree C start to work for allergies, and how long does the effect last?

Official product information states that the medicine's activity has been shown to persist for at least 24 hours. The body clears the drug slowly, with an average elimination half-life of 8 to 9 hours in adults with normal kidney function. Regulatory documents also note that the concentration of the medicine in the blood does not directly reflect its effect on allergic skin reactions.

Q: Can I operate a car or machinery after taking Alerfree C?

Regulatory documents caution against engaging in hazardous activities, such as driving or operating heavy machinery, that require complete mental alertness. This warning is based on the potential for the medicine to cause common side effects like somnolence (sleepiness), fatigue, or unusual weakness.

Q: Does Alerfree C contain any ingredients other than the allergy medicine?

The active therapeutic ingredient is a single component: levocetirizine dihydrochloride. The official documents list the inactive ingredients, known as excipients, that are included in the tablets and solutions to help form the medicine and facilitate consumption.

Q: Is it safe to take Alerfree C with food or non-alcoholic drinks?

Official regulatory information indicates that taking the medicine with food does not change the total amount of the drug the body absorbs. However, eating food may delay the time it takes for the medicine to reach its peak concentration in the bloodstream and slightly lower that peak concentration.

Q: What is a 'contraindication' and how do I know if I have one for Alerfree C?

A contraindication is a specific health condition that official documents describe as prohibiting the use of the medicine. Conditions include a known severe allergy (hypersensitivity) to levocetirizine or related compounds, and having end-stage renal disease (very severe kidney impairment).

Q: Are there any special warnings for older adults taking Alerfree C?

Regulatory documents note that the use of this drug in older adults requires consideration of dose adjustment due to the higher probability of reduced kidney function associated with age. The clearance of the medicine is slower in people with decreased kidney function, which is a consideration for use in this population.

Q: Is Alerfree C a generic or brand-name medicine?

The name Levocetirizine dihydrochloride refers to the active chemical substance. This substance is available commercially both under various brand names and also as a general-purpose generic medicine.

Q: Will Alerfree C help with my pet allergies?

Studies and official product information indicate that the medicine is approved for treating symptoms related to perennial allergic rhinitis. This condition is caused by year-round allergens, which commonly include those derived from pets, and the medicine is indicated for these associated symptoms.

Q: Will Alerfree C affect my allergy skin test results?

Official regulatory information states that antihistamines can suppress the skin's response to allergy tests. Official documents recommend a temporary discontinuation of the medicine, often for about 3 days (a 'wash-out period'), before these skin tests are conducted.

Official Storage Requirements

Regulatory documents define specific conditions for storing Alerfree C (Levocetirizine dihydrochloride) to maintain its stability. The medication must be kept at a controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). To protect the product, it is mandatory to keep it from freezing and to store it away from direct moisture and light. It is essential to keep the tablets or solution in the original, tightly closed container and to discard any unused product after the official expiration date.

Required Safety and Disposal

As a mandatory safety precaution, Alerfree C must be stored out of the sight and reach of children and pets. For disposal of unused or expired medication, official guidelines recommend using a drug take-back program. It is strictly advised not to flush the medication down the toilet or sink, and measures must be taken during disposal to prevent its release into the environment.